References:
Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, et al.(2010). Regression of castrate-recurrent prostate cancer by a
small-molecule inhibitor of the amino-terminus domain of the androgen
receptor. Cancer Cell 17: 535-546.
Azeem W, Hellem MR, Olsen JR, Hua Y, Marvyin K, Qu Y, et al.(2017). An androgen response element driven reporter assay for the
detection of androgen receptor activity in prostate cells. PLoS One
12: e0177861.
Balk SP (2002). Androgen receptor as a target in androgen-independent
prostate cancer. Urology 60: 132-138; discussion 138-139.
Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald
TY, et al. (2013). Targeted next-generation sequencing of
advanced prostate cancer identifies potential therapeutic targets and
disease heterogeneity. Eur Urol 63: 920-926.
Bird GH, Lajmi AR, & Shin JA (2002). Sequence-specific recognition of
DNA by hydrophobic, alanine-rich mutants of the basic region/leucine
zipper motif investigated by fluorescence anisotropy. Biopolymers
65: 10-20.
Caboni L, & Lloyd DG (2013). Beyond the ligand-binding pocket:
targeting alternate sites in nuclear receptors. Med Res Rev 33:1081-1118.
Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al.(2004). Molecular determinants of resistance to antiandrogen therapy.
Nat Med 10: 33-39.
Claessens F, Denayer S, Van Tilborgh N, Kerkhofs S, Helsen C, & Haelens
A (2008). Diverse roles of androgen receptor (AR) domains in AR-mediated
signaling. Nucl Recept Signal 6: e008.
Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A,
et al. (1994). Androgen receptor activation in prostatic tumor cell
lines by insulin-like growth factor-I, keratinocyte growth factor, and
epidermal growth factor. Cancer Res 54: 5474-5478.
Dalal K, Ban F, Li H, Morin H, Roshan-Moniri M, Tam KJ, et al.(2018). Selectively targeting the dimerization interface of human
androgen receptor with small-molecules to treat castration-resistant
prostate cancer. Cancer Lett 437: 35-43.
Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hassona MD, et
al. (2014). Selectively targeting the DNA-binding domain of the
androgen receptor as a prospective therapy for prostate cancer. J Biol
Chem 289: 26417-26429.
Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, & Tindall DJ (2008).
Splicing of a novel androgen receptor exon generates a constitutively
active androgen receptor that mediates prostate cancer therapy
resistance. Cancer Res 68: 5469-5477.
Denayer S, Helsen C, Thorrez L, Haelens A, & Claessens F (2010). The
rules of DNA recognition by the androgen receptor. Mol Endocrinol
24: 898-913.
Deslypere JP, Young M, Wilson JD, & McPhaul MJ (1992). Testosterone and
5 alpha-dihydrotestosterone interact differently with the androgen
receptor to enhance transcription of the MMTV-CAT reporter gene. Mol
Cell Endocrinol 88: 15-22.
Duff MR, Jr., Grubbs J, & Howell EE (2011). Isothermal titration
calorimetry for measuring macromolecule-ligand affinity. J Vis Exp.
Dupaul-Chicoine J, Yeretssian G, Doiron K, Bergstrom KSB, McIntire CR,
LeBlanc PM, et al. (2010). Control of Intestinal Homeostasis,
Colitis, and Colitis-Associated Colorectal Cancer by the Inflammatory
Caspases. Immunity 32: 367-378.
Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley
GJ, et al. (1997). Functional characterization of mutant androgen
receptors from androgen-independent prostate cancer. Clin Cancer Res
3: 1383-1388.
Gao W, Bohl CE, & Dalton JT (2005). Chemistry and structural biology of
androgen receptor. Chem Rev 105: 3352-3370.
Gottlieb B, Beitel LK, Nadarajah A, Paliouras M, & Trifiro M (2012).
The androgen receptor gene mutations database: 2012 update. Hum Mutat
33: 887-894.
Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et
al. (2012). The mutational landscape of lethal castration-resistant
prostate cancer. Nature 487: 239-243.
Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS, et al.(2004). Epidermal growth factor increases coactivation of the androgen
receptor in recurrent prostate cancer. The Journal of biological
chemistry 279: 7119-7130.
Guntur AR, & Rosen CJ (2013). IGF-1 regulation of key signaling
pathways in bone. Bonekey Rep 2: 437.
Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al. (2009). A
novel androgen receptor splice variant is up-regulated during prostate
cancer progression and promotes androgen depletion-resistant growth.
Cancer Res 69: 2305-2313.
Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, et
al. (2003). Novel mutations of androgen receptor: a possible mechanism
of bicalutamide withdrawal syndrome. Cancer Res 63: 149-153.
Hellman LM, & Fried MG (2007). Electrophoretic mobility shift assay
(EMSA) for detecting protein-nucleic acid interactions. Nat Protoc
2: 1849-1861.
Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, & Hittmair A
(1995). Distant metastases from prostatic carcinoma express androgen
receptor protein. Cancer Res 55: 3068-3072.
Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, & Hittmair A
(1996). Androgen receptor status of lymph node metastases from prostate
cancer. Prostate 28: 129-135.
Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al.(2009). Ligand-independent androgen receptor variants derived from
splicing of cryptic exons signify hormone-refractory prostate cancer.
Cancer Res 69: 16-22.
Iwamura M, Sluss PM, Casamento JB, & Cockett AT (1993). Insulin-like
growth factor I: action and receptor characterization in human prostate
cancer cell lines. Prostate 22: 243-252.
Kaufman M, & Pinsky L (1983). The dissociation of testosterone- and 5
alpha-dihydrotestosterone-receptor complexes formed within cultured
human genital skin fibroblasts. J Steroid Biochem 18: 121-125.
Kim HJ, Park YI, & Dong MS (2006). Comparison of prostate cancer cell
lines for androgen receptor-mediated reporter gene assays. Toxicol In
Vitro 20: 1159-1167.
Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, et al.(2013). An F876L mutation in androgen receptor confers genetic and
phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov
3: 1030-1043.
Kuiper GG, & Brinkmann AO (1995). Phosphotryptic peptide analysis of
the human androgen receptor: detection of a hormone-induced
phosphopeptide. Biochemistry 34: 1851-1857.
Lallous N, Dalal K, Cherkasov A, & Rennie PS (2013). Targeting
alternative sites on the androgen receptor to treat castration-resistant
prostate cancer. Int J Mol Sci 14: 12496-12519.
Lallous N, Volik SV, Awrey S, Leblanc E, Tse R, Murillo J, et al.(2016). Functional analysis of androgen receptor mutations that confer
anti-androgen resistance identified in circulating cell-free DNA from
prostate cancer patients. Genome Biol 17: 10.
Li W, Ouyang Z, Zhang Q, Wang L, Shen Y, Wu X, et al. (2014).
SBF-1 exerts strong anticervical cancer effect through inducing
endoplasmic reticulum stress-associated cell death via targeting
sarco/endoplasmic reticulum Ca(2+)-ATPase 2. Cell Death Dis 5:e1581.
Li W, Song R, Fang X, Wang L, Chen W, Tang P, et al. (2012).
SBF-1, a synthetic steroidal glycoside, inhibits melanoma growth and
metastasis through blocking interaction between PDK1 and AKT3. Biochem
Pharmacol 84: 172-181.
Li X, Zhang C, Shi Q, Yang T, Zhu Q, Tian Y, et al. (2013).
Improving the efficacy of conventional therapy by adding andrographolide
sulfonate in the treatment of severe hand, foot, and mouth disease: a
randomized controlled trial. Evidence-based complementary and
alternative medicine : eCAM 2013: 316250.
Linja MJ, Savinainen KJ, Saramäki OR, Tammela TL, Vessella RL, &
Visakorpi T (2001). Amplification and overexpression of androgen
receptor gene in hormone-refractory prostate cancer. Cancer Res
61: 3550-3555.
McKeehan WL, Adams PS, & Rosser MP (1984). Direct mitogenic effects of
insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown
pituitary factors and possibly prolactin, but not androgen, on normal
rat prostate epithelial cells in serum-free, primary cell culture.
Cancer Res 44: 1998-2010.
Mohler JL, Titus MA, Bai S, Kennerley BJ, Lih FB, Tomer KB, et
al. (2011). Activation of the androgen receptor by intratumoral
bioconversion of androstanediol to dihydrotestosterone in prostate
cancer. Cancer Res 71: 1486-1496.
Paul R, & Breul J (2000). Antiandrogen withdrawal syndrome associated
with prostate cancer therapies: incidence and clinical significance.
Drug Saf 23: 381-390.
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera
JM, et al. (2015). Integrative clinical genomics of advanced
prostate cancer. Cell 161: 1215-1228.
Sadi MV, & Barrack ER (1991). Determination of growth fraction in
advanced prostate cancer by Ki-67 immunostaining and its relationship to
the time to tumor progression after hormonal therapy. Cancer
67: 3065-3071.
Schaufele F, Carbonell X, Guerbadot M, Borngraeber S, Chapman MS, Ma
AAK, et al. (2005). The structural basis of androgen receptor
activation: intramolecular and intermolecular amino-carboxy
interactions. Proc Natl Acad Sci USA 102: 9802-9807.
Shaffer PL, Jivan A, Dollins DE, Claessens F, & Gewirth DT (2004).
Structural basis of androgen receptor binding to selective androgen
response elements. Proc Natl Acad Sci USA 101: 4758-4763.
Siegel RL, Miller KD, & Jemal A (2019). Cancer statistics, 2019. CA
Cancer J Clin 69: 7-34.
Skala W, Goettig P, & Brandstetter H (2013). Do-it-yourself
histidine-tagged bovine enterokinase: a handy member of the protein
engineer’s toolbox. J Biotechnol 168: 421-425.
Steinkamp MP, O’Mahony OA, Brogley M, Rehman H, Lapensee EW,
Dhanasekaran S, et al. (2009). Treatment-dependent androgen
receptor mutations in prostate cancer exploit multiple mechanisms to
evade therapy. Cancer Res 69: 4434-4442.
Steketee K, Timmerman L, Ziel-van der Made AC, Doesburg P, Brinkmann AO,
& Trapman J (2002). Broadened ligand responsiveness of androgen
receptor mutants obtained by random amino acid substitution of H874 and
mutation hot spot T877 in prostate cancer. Int J Cancer 100:309-317.
Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA,
et al. (2010a). Castration resistance in human prostate cancer is
conferred by a frequently occurring androgen receptor splice variant. J
Clin Invest 120: 2715-2730.
Sun Y, Wu XX, Yin Y, Gong FY, Shen Y, Cai TT, et al. (2010b).
Novel immunomodulatory properties of cirsilineol through selective
inhibition of IFN-gamma signaling in a murine model of inflammatory
bowel disease. Biochem Pharmacol 79: 229-238.
Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, et al.(1997). Dehydroepiandrosterone activates mutant androgen receptors
expressed in the androgen-dependent human prostate cancer xenograft
CWR22 and LNCaP cells. Mol Endocrinol 11: 450-459.
Taplin M-E, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J,
et al. (2003). Androgen receptor mutations in androgen-independent
prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol
21: 2673-2678.
Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, et
al. (1999). Selection for androgen receptor mutations in prostate
cancers treated with androgen antagonist. Cancer Res 59:2511-2515.
Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK,
et al. (1995). Mutation of the androgen-receptor gene in metastatic
androgen-independent prostate cancer. N Engl J Med 332:1393-1398.
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS,
et al. (2010). Integrative genomic profiling of human prostate cancer.
Cancer Cell 18: 11-22.
Tian X, He Y, & Zhou J (2015). Progress in antiandrogen design
targeting hormone binding pocket to circumvent mutation based
resistance. Front Pharmacol 6: 57.
Tilley WD, Lim-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR, & Skinner
JM (1994). Detection of discrete androgen receptor epitopes in prostate
cancer by immunostaining: measurement by color video image analysis.
Cancer Res 54: 4096-4102.
Tzivion G, Dobson M, & Ramakrishnan G (2011). FoxO transcription
factors; Regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta
1813: 1938-1945.
van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC,
Mulder E, Boersma W, et al. (1991). Androgen receptors in
endocrine-therapy-resistant human prostate cancer. Int J Cancer
48: 189-193.
Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C,
Claassen E, et al. (1990). A mutation in the ligand binding
domain of the androgen receptor of human LNCaP cells affects steroid
binding characteristics and response to anti-androgens. Biochem Biophys
Res Commun 173: 534-540.
Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg
C, et al. (1995). In vivo amplification of the androgen receptor
gene and progression of human prostate cancer. Nat Genet 9:401-406.
Wang F, Liu XQ, Li H, Liang KN, Miner JN, Hong M, et al. (2006).
Structure of the ligand-binding domain (LBD) of human androgen receptor
in complex with a selective modulator LGD2226. Acta Crystallogr Sect F
Struct Biol Cryst Commun 62: 1067-1071.
Watson PA, Arora VK, & Sawyers CL (2015). Emerging mechanisms of
resistance to androgen receptor inhibitors in prostate cancer. Nat Rev
Cancer 15: 701-711.
Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, et
al. (2010). Constitutively active androgen receptor splice variants
expressed in castration-resistant prostate cancer require full-length
androgen receptor. Proc Natl Acad Sci U S A 107: 16759-16765.
Wienken CJ, Baaske P, Rothbauer U, Braun D, & Duhr S (2010).
Protein-binding assays in biological liquids using microscale
thermophoresis. Nat Commun 1: 100.
Wong HY, Burghoorn JA, Van Leeuwen M, De Ruiter PE, Schippers E, Blok
LJ, et al. (2004). Phosphorylation of androgen receptor isoforms.
Biochem J 383: 267-276.
Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y,
et al. (2005). Antiandrogen bicalutamide promotes tumor growth in a
novel androgen-dependent prostate cancer xenograft model derived from a
bicalutamide-treated patient. Cancer Res 65: 9611-9616.
Zhao Y, Tindall DJ, & Huang H (2014). Modulation of androgen receptor
by FOXA1 and FOXO1 factors in prostate cancer. Int J Biol Sci
10: 614-619.
Zheng D, Zhu G, Liao S, Yi W, Luo G, He J, et al. (2015).
Dysregulation of the PI3K/Akt signaling pathway affects cell cycle and
apoptosis of side population cells in nasopharyngeal carcinoma. Oncol
Lett 10: 182-188.
Zheng W, Wang H, Zeng Z, Lin J, Little PJ, Srivastava LK, et al.(2012). The possible role of the Akt signaling pathway in schizophrenia.
Brain Res 1470: 145-158.
Zhou XE, Suino-Powell K, Ludidi PL, McDonnell DP, & Xu HE (2010).
Expression, purification and primary crystallographic study of human
androgen receptor in complex with DNA and coactivator motifs. Protein
Expr Purif 71: 21-27.
Zhu GC, Yu CY, She L, Tan HL, Li G, Ren SL, et al. (2015).
Metadherin regulation of vascular endothelial growth factor expression
is dependent upon the PI3K/Akt pathway in squamous cell carcinoma of the
head and neck. Medicine (Baltimore) 94: e502.